Literature DB >> 21382394

Overview of adjuvant trials of aromatase inhibitors in early breast cancer.

James N Ingle1.   

Abstract

The third-generation aromatase inhibitors are an important class of drugs for use in adjuvant therapy for postmenopausal women with resected estrogen receptor positive breast cancer. Multiple large prospective randomized trials have established their value in this setting and provided guidance for their use in clinical management. This review will outline the trials that have provided evidence on the value of the aromatase inhibitors in the adjuvant setting as well as the ongoing trials that will expand our knowledge of how to use them most effectively.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21382394     DOI： 10.1016/j.steroids.2011.02.021

Source DB:  PubMed          Journal:  Steroids        ISSN： 0039-128X            Impact factor:   2.668


  9 in total

1.  Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.

Authors:  Mohan Liu; Paul E Goss; James N Ingle; Michiaki Kubo; Yoichi Furukawa; Anthony Batzler; Gregory D Jenkins; Erin E Carlson; Yusuke Nakamura; Daniel J Schaid; Judy-Anne W Chapman; Lois E Shepherd; Matthew J Ellis; Sundeep Khosla; Liewei Wang; Richard M Weinshilboum
Journal:  Mol Endocrinol       Date:  2014-08-22

2.  Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.

Authors:  James N Ingle; Junmei Cairns; Vera J Suman; Lois E Shepherd; Peter A Fasching; Tanya L Hoskin; Ravinder J Singh; Zeruesenay Desta; Krishna R Kalari; Matthew J Ellis; Paul E Goss; Bingshu E Chen; Bernhard Volz; Poulami Barman; Erin E Carlson; Tufia Haddad; Matthew P Goetz; Barbara Goodnature; Matthew E Cuellar; Michael A Walters; Cristina Correia; Scott H Kaufmann; Richard M Weinshilboum; Liewei Wang
Journal:  Clin Cancer Res       Date:  2020-02-25       Impact factor: 12.531

3.  Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.

Authors:  James N Ingle; Krishna R Kalari; Aman U Buzdar; Mark E Robson; Matthew P Goetz; Zeruesenay Desta; Poulami Barman; Tanda T Dudenkov; Donald W Northfelt; Edith A Perez; David A Flockhart; Clark V Williard; Liewei Wang; Richard M Weinshilboum
Journal:  Steroids       Date:  2014-08-24       Impact factor: 2.668

4.  Evaluation of the Aromatase Inhibition Potential of Freeze-Dried Grape Powder.

Authors:  Summer V Allen; Sandhya Pruthi; Vera J Suman; Tanya L Hoskin; Celine M Vachon; James N Ingle; Janet E Olson
Journal:  J Diet Suppl       Date:  2014-08-28

5.  Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression.

Authors:  Mohan Liu; Liewei Wang; Tim Bongartz; John R Hawse; Svetomir N Markovic; Daniel J Schaid; Taisei Mushiroda; Michiaki Kubo; Yusuke Nakamura; Naoyuki Kamatani; Paul E Goss; James N Ingle; Richard M Weinshilboum
Journal:  Breast Cancer Res       Date:  2012-03-09       Impact factor: 6.466

6.  Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.

Authors:  Kristina Bojanic; Lucija Kuna; Ines Bilic Curcic; Jasenka Wagner; Robert Smolic; Kristina Kralik; Tomislav Kizivat; Gordana Ivanac; Aleksandar Vcev; George Y Wu; Martina Smolic
Journal:  Int J Environ Res Public Health       Date:  2020-05-23       Impact factor: 3.390

7.  Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.

Authors:  James N Ingle; Krishna R Kalari; Poulami Barman; Lois E Shepherd; Matthew J Ellis; Paul E Goss; Aman U Buzdar; Mark E Robson; Junmei Cairns; Erin E Carlson; Abraham Eyman Casey; Tanya L Hoskin; Barbara A Goodnature; Tufia C Haddad; Matthew P Goetz; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2021-01       Impact factor: 2.000

Review 8.  Pharmacogenomics of endocrine therapy in breast cancer.

Authors:  James N Ingle
Journal:  J Hum Genet       Date:  2013-05-02       Impact factor: 3.172

9.  Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy.

Authors:  Kristina Bojanić; Ines Bilić Ćurčić; Lucija Kuna; Tomislav Kizivat; Robert Smolic; Nikola Raguž Lučić; Kristina Kralik; Vatroslav Šerić; Gordana Ivanac; Sandra Tucak-Zorić; Aleksandar Včev; Martina Smolić
Journal:  J Clin Med       Date:  2018-09-17       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.